Want to see MDCX full AI Analyst Report?
MDCX Stock Chart & Stats
$1.46
-$0.29(-9.70%)
At close: 4:00 PM EST
$1.46
-$0.29(-9.70%)
Day’s Range― - ―
52-Week Range$0.25 - $3.35
Previous CloseN/A
Volume5.92K
Average Volume (3M)2.21M
Market Cap
$23.94M
Enterprise Value$1.56M
Total Cash (Recent Filing)$6.37M
Total Debt (Recent Filing)$169.62K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 20, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding56,658,165
10 Day Avg. Volume1,019,285
30 Day Avg. Volume2,210,102
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-391.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap0.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$5.50Price Target Upside276.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest Near-term LeverageLow reported leverage (debt-to-equity ~0.13) reduces immediate interest and solvency pressure for a pre-revenue biotech. This structural cushion gives management room to prioritize R&D and clinical milestones before needing aggressive deleveraging or highly dilutive financing.
Secured Financing Extends RunwayThe completed $22.86M secured financing provides material near-term capital to fund clinical programs, business development and repay prior debt. For a pre-revenue company, this financing structurally extends runway and supports executing on development milestones without immediate revenue generation.
Expanded ATM Increases Capital AccessA larger $50M ATM program and $11.5M raised to date mean recurring, programmatic access to public equity. For an early-stage biotech with long R&D timelines, reliable market access is a durable structural advantage that enables episodic capital raises aligned to milestone timing.
Bears Say
Pre-revenue With Widening LossesThe company reports no revenue and materially widening operating losses across periods, reflecting no operating leverage and a long path to commercialization. Persistent, growing losses force ongoing external funding and increase execution risk for clinical programs over the medium term.
Substantial And Rising Cash BurnNegative operating cash flow and free cash flow at large absolute levels mean internal cash generation is insufficient to sustain R&D. Sustained burn rates create continual refinancing needs, raising the probability of dilutive raises or restrictive financing that can constrain strategic flexibility.
Nasdaq Non-compliance And Dilution RiskOutstanding Nasdaq bid-price and listing-standard notices create structural urgency to raise capital or restructure the equity base. That pressure, coupled with recent ATM and secured financings, increases the likelihood of dilution, asset encumbrances or emergency measures that can undermine long-term shareholder liquidity and governance.
Medicus Pharma Ltd News
MDCX FAQ
What was Medicus Pharma Ltd’s price range in the past 12 months?
Medicus Pharma Ltd lowest stock price was $0.25 and its highest was $3.35 in the past 12 months.
What is Medicus Pharma Ltd’s market cap?
Medicus Pharma Ltd’s market cap is $23.94M.
When is Medicus Pharma Ltd’s upcoming earnings report date?
Medicus Pharma Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 39 days.
How were Medicus Pharma Ltd’s earnings last quarter?
Medicus Pharma Ltd released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.118.
Is Medicus Pharma Ltd overvalued?
According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued.
Does Medicus Pharma Ltd pay dividends?
Medicus Pharma Ltd does not currently pay dividends.
What is Medicus Pharma Ltd’s EPS estimate?
Medicus Pharma Ltd’s EPS estimate is -0.13.
How many shares outstanding does Medicus Pharma Ltd have?
Medicus Pharma Ltd has 56,658,165 shares outstanding.
What happened to Medicus Pharma Ltd’s price movement after its last earnings report?
Medicus Pharma Ltd reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went down -10.682%.
Which hedge fund is a major shareholder of Medicus Pharma Ltd?
Currently, no hedge funds are holding shares in MDCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicus Pharma Ltd
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
MDCX Stock 12 Month Forecast
Average Price Target
$5.50
▲(276.71% Upside)
Technical Analysis
Ovid Therapeutics
―
Jasper Therapeutics
―
Cognition Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
0.48% Insiders
<0.01% Mutual Funds
3.11% Other Institutional Investors
96.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---